Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Similar immune responses to alpha1-oleate and Bacillus Calmette-Guérin treatment in patients with bladder cancer

S. Ahmadi, I. Ambite, A. Brisuda, J. Háček, F. Haq, S. Sabari, K. Vanarsa, C. Mohan, M. Babjuk, C. Svanborg

. 2024 ; 13 (7) : e7091. [pub] -

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24014419

Grant support
Vetenskapsrådet
HAMLET BioPharma
Cancerfonden
954360 European Union's Horizon 2020 research and innovation program
Royal Physiographic Society in Lund

BACKGROUND: The molecular content of urine is defined by filtration in the kidneys and by local release from tissues lining the urinary tract. Pathological processes and different therapies change the molecular composition of urine and a variety of markers have been analyzed in patients with bladder cancer. The response to BCG immunotherapy and chemotherapy has been extensively studied and elevated urine concentrations of IL-1RA, IFN-α, IFN-γ TNF-α, and IL-17 have been associated with improved outcome. METHODS: In this study, the host response to intravesical alpha 1-oleate treatment was characterized in patients with non-muscle invasive bladder cancer by proteomic and transcriptomic analysis. RESULTS: Proteomic profiling detected a significant increase in multiple cytokines in the treatment group compared to placebo. The innate immune response was strongly activated, including IL-1RA and pro-inflammatory cytokines in the IL-1 family (IL-1α, IL-1β, IL-33), chemokines (MIP-1α, IL-8), and interferons (IFN-α2, IFN-γ). Adaptive immune mediators included IL-12, Granzyme B, CD40, PD-L1, and IL-17D, suggesting broad effects of alpha 1-oleate treatment on the tumor tissues. CONCLUSIONS: The cytokine response profile in alpha 1-oleate treated patients was similar to that reported in BCG treated patients, suggesting a significant overlap. A reduction in protein levels at the end of treatment coincided with inhibition of cancer-related gene expression in tissue biopsies, consistent with a positive treatment effect. Thus, in addition to killing tumor cells and inducing cell detachment, alpha 1-oleate is shown to activate a broad immune response with a protective potential.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014419
003      
CZ-PrNML
005      
20240905134203.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.7091 $2 doi
035    __
$a (PubMed)38553868
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ahmadi, Shahram $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden $1 https://orcid.org/0000000150697131
245    10
$a Similar immune responses to alpha1-oleate and Bacillus Calmette-Guérin treatment in patients with bladder cancer / $c S. Ahmadi, I. Ambite, A. Brisuda, J. Háček, F. Haq, S. Sabari, K. Vanarsa, C. Mohan, M. Babjuk, C. Svanborg
520    9_
$a BACKGROUND: The molecular content of urine is defined by filtration in the kidneys and by local release from tissues lining the urinary tract. Pathological processes and different therapies change the molecular composition of urine and a variety of markers have been analyzed in patients with bladder cancer. The response to BCG immunotherapy and chemotherapy has been extensively studied and elevated urine concentrations of IL-1RA, IFN-α, IFN-γ TNF-α, and IL-17 have been associated with improved outcome. METHODS: In this study, the host response to intravesical alpha 1-oleate treatment was characterized in patients with non-muscle invasive bladder cancer by proteomic and transcriptomic analysis. RESULTS: Proteomic profiling detected a significant increase in multiple cytokines in the treatment group compared to placebo. The innate immune response was strongly activated, including IL-1RA and pro-inflammatory cytokines in the IL-1 family (IL-1α, IL-1β, IL-33), chemokines (MIP-1α, IL-8), and interferons (IFN-α2, IFN-γ). Adaptive immune mediators included IL-12, Granzyme B, CD40, PD-L1, and IL-17D, suggesting broad effects of alpha 1-oleate treatment on the tumor tissues. CONCLUSIONS: The cytokine response profile in alpha 1-oleate treated patients was similar to that reported in BCG treated patients, suggesting a significant overlap. A reduction in protein levels at the end of treatment coincided with inhibition of cancer-related gene expression in tissue biopsies, consistent with a positive treatment effect. Thus, in addition to killing tumor cells and inducing cell detachment, alpha 1-oleate is shown to activate a broad immune response with a protective potential.
650    _2
$a lidé $7 D006801
650    12
$a BCG vakcína $x terapeutické užití $7 D001500
650    _2
$a antagonista receptoru pro interleukin 1 $x terapeutické užití $7 D053590
650    _2
$a kyselina olejová $7 D019301
650    _2
$a proteomika $7 D040901
650    _2
$a cytokiny $7 D016207
650    12
$a nádory močového měchýře $x patologie $7 D001749
650    _2
$a interferon alfa $x farmakologie $x terapeutické užití $7 D016898
650    _2
$a imunita $7 D007109
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ambite, Ines $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden $1 https://orcid.org/000000031470671X
700    1_
$a Brisuda, Antonín $u Department of Urology, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
700    1_
$a Háček, Jaromír $u Department of Pathology and Molecular Medicine, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
700    1_
$a Haq, Farhan $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Sabari, Samudra $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Vanarsa, Kamala $u Department of Biomedical Engineering, University of Houston, Houston, Texas, USA
700    1_
$a Mohan, Chandra $u Department of Biomedical Engineering, University of Houston, Houston, Texas, USA
700    1_
$a Babjuk, Marek $u Department of Urology, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
700    1_
$a Svanborg, Catharina $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 13, č. 7 (2024), s. e7091
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38553868 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134157 $b ABA008
999    __
$a ok $b bmc $g 2143905 $s 1226285
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 7 $d e7091 $e - $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
GRA    __
$p Vetenskapsrådet
GRA    __
$p HAMLET BioPharma
GRA    __
$p Cancerfonden
GRA    __
$a 954360 $p European Union's Horizon 2020 research and innovation program
GRA    __
$p Royal Physiographic Society in Lund
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options